The IDE Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population targeting the IDE gene in the HT29 human colorectal adenocarcinoma cell line. This heterogeneous pool harbors loss-of-function mutations generated by CRISPR/Cas9-mediated gene disruption, providing a genetically diverse model for IDE loss without clonal selection. Such polyclonal populations retain population-level heterogeneity, which can be advantageous for certain phenotypic studies.
The parental HT29 cell line originates from a primary colorectal adenocarcinoma in a female patient and serves as a well-characterized epithelial model in cancer research. These cells exhibit hallmark features of colorectal cancer, including dysregulated signaling and metabolic reprogramming. HT29 is routinely used to study proliferation, apoptosis, and drug responses, making it a suitable host for investigating the metabolic and oncogenic consequences of IDE knockout.
IDE encodes insulin-degrading enzyme, a zinc metalloprotease that degrades insulin, glucagon, and amyloid-beta peptides, thereby regulating insulin signaling and proteostasis. Its activity is modulated by upstream regulators such as insulin, PPARG, and glucose, and it directly interacts with substrates and cofactors including ATP and proteasome subunits. IDE functions within networks involving INSR, IRS1, PI3K, and AKT, and influences the amyloidogenic pathway through APP, BACE1, and PSEN1. Disruption of IDE leads to impaired substrate clearance, enhancing insulin availability and amyloid-beta accumulation.
In HT29 colorectal cancer cells, IDE knockout is expected to amplify insulin signaling via reduced insulin degradation, potentially hyperactivating downstream effectors such as AKT and ERK and promoting proliferation. This model enables dissection of how dysregulated insulin turnover supports tumor growth and intersects with oncogenic pathways. Additionally, amyloid-beta accumulation in this cancer background offers a unique system to study the interplay between metabolic and neurodegenerative processes, providing insights relevant to both cancer biology and Alzheimer’s disease.
Applications include insulin signaling analysis via Western blotting for phospho-AKT and phospho-ERK, insulin degradation assays, and amyloid-beta clearance experiments. Cell proliferation and apoptosis can be assessed by MTT assay and flow cytometry, respectively. This IDE knockout polyclonal pool is also suitable for drug screening targeting IDE or insulin/AKT pathways, and for mechanistic studies in diabetes, metabolic syndrome, and cancer metabolism. For further information, please contact Ascent Research.
